AML・FCPA：Alexion ､トルコとロシアで贈賄：2140万ドルの罰金（動画）：
Alexion Pharmaceuticals pays SEC $21.4 million to resolve FCPA offenses：
Alexion Pharmaceuticals向SEC支付2140万美元以解决FCPA违法行为
AML・FCPA：
Alexion：
コネチカット本拠のAlexion Pharmaceuticals、Inc.。
SEC・FCPA違反で、$ 2140万支払うことに同意しました
同社は、トルコとロシアの外務省に贈賄したことでFCPAに違反。
また、ブラジルとコロンビア子会社で、帳簿記録違反とのこと。
SECは、木曜日、内部統制違反でアレクシオンを起訴しました。
350万ドルのペナルティに加え、1420万ドルの不正利得返還金と約380万ドルの予見利息を支払います。
The investigation started in 2015, according to the company’s earlier SEC filings.
In May this year, Alexion said it received a declination from the DOJ for the FCPA investigation.
In Turkey and Russia,
Alexion paid government officials and doctors at state-connected hospitals to promote use of its blood-disease drug, Soliris.
Alexion retained a consultant in Turkey from 2010 to 2015 with ties to health officials.
Alexion Turkey paid the consultant over $1.3 million for “consulting fees and purported expense reimbursements,” the SEC said.
Alexion employees in Turkey “received limited training regarding anti-bribery compliance,” according to the the SEC order.
In Russia,
Alexion paid doctors at government hospitals over $1 million from 2011 to 2015 to increase Soliris prescriptions.
Alexion Russia recorded the payments as “honoraria, educational expenses, business meeting expenses, and scientific research.”
The bribery resulted in Alexion being “unjustly enriched” by about $6.6 million in Turkey and $7.5 million in Russia, the SEC said.
The FCPA Blog